New research from Project Scientists, Jacob Torres

Dr. Jacob Torres and the Weimbs' Lab at UCSB published new research on the potential of ketogenic metabolic therapy in addressing polycystic kidney disease (PKD). The study highlights that PKD is linked to metabolic dysfunction, specifically increased glycolysis. Findings show that both fasting and time-restricted feeding can slow or even reverse PKD progression in animal models, with the key metabolite β-hydroxybutyrate (BHB) replicating these benefits. This suggests that BHB, produced during ketosis, plays a critical role in modifying disease progression, offering promising new avenues for future PKD therapies.